Back to today’s briefing

Story perspectives

Tariff Deadline Threatens U.S. Pharma Supply Chain Stability

5/12/2025

50 9

Summary

Story summary

As the mid-May deadline looms for tariffs on pharmaceutical imports, the U.S. grapples with potential supply chain disruptions. President Trump’s executive order seeks to enhance domestic production, yet experts caution that a robust industrial policy is essential. Rising tariffs could inflate biotech manufacturing costs, possibly driving clinical trials overseas for better financial and regulatory conditions.

1 of 1

Story summary

As the mid-May deadline looms for tariffs on pharmaceutical imports, the U.S. grapples with potential supply chain disruptions. President Trump’s executive order seeks to enhance domestic production, yet experts caution that a robust industrial policy is essential. Rising tariffs could inflate biotech manufacturing costs, possibly driving clinical trials overseas for better financial and regulatory conditions.